HK1247820A1 - 預防或治療代謝綜合症的方法 - Google Patents

預防或治療代謝綜合症的方法

Info

Publication number
HK1247820A1
HK1247820A1 HK18107245.8A HK18107245A HK1247820A1 HK 1247820 A1 HK1247820 A1 HK 1247820A1 HK 18107245 A HK18107245 A HK 18107245A HK 1247820 A1 HK1247820 A1 HK 1247820A1
Authority
HK
Hong Kong
Prior art keywords
preventing
methods
metabolic syndrome
treating metabolic
treating
Prior art date
Application number
HK18107245.8A
Other languages
English (en)
Inventor
黑茲爾‧H‧司徒
Original Assignee
康奈爾大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 康奈爾大學 filed Critical 康奈爾大學
Publication of HK1247820A1 publication Critical patent/HK1247820A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK18107245.8A 2009-08-12 2018-06-01 預防或治療代謝綜合症的方法 HK1247820A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23327509P 2009-08-12 2009-08-12

Publications (1)

Publication Number Publication Date
HK1247820A1 true HK1247820A1 (zh) 2018-10-05

Family

ID=43586452

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107245.8A HK1247820A1 (zh) 2009-08-12 2018-06-01 預防或治療代謝綜合症的方法

Country Status (10)

Country Link
US (4) US20110039766A1 (zh)
EP (4) EP3427746A1 (zh)
JP (5) JP5909182B2 (zh)
CN (3) CN107412724A (zh)
CA (1) CA2770688C (zh)
DK (1) DK2464371T3 (zh)
ES (1) ES2576746T3 (zh)
HK (1) HK1247820A1 (zh)
HU (1) HUE029550T2 (zh)
WO (1) WO2011019809A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3708178T (pt) 2009-08-24 2023-11-16 Stealth Biotherapeutics Inc Peptídeo para uso ao prevenir ou tratar a degeneração macular
EP2944317A1 (en) * 2009-10-05 2015-11-18 Cornell University Methods for the prevention or treatment of heart failure
WO2011082328A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
AU2013237827B2 (en) * 2012-03-30 2017-12-14 Stealth Biotherapeutics Inc. Methods and compositions for the prevention and treatment neuropathy
CA2880648A1 (en) 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
BR112015009072A2 (pt) * 2012-10-22 2017-07-04 Henry Ford Health Systems métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
CN116474071A (zh) * 2013-03-01 2023-07-25 康德生物医疗有限公司 治疗线粒体疾病的方法
WO2014134554A1 (en) 2013-03-01 2014-09-04 Stealth Peptides International, Inc. Methods and compositions for the prevention or treatment of barth syndrome
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
WO2015048522A1 (en) * 2013-09-27 2015-04-02 Cornell University Use of aromatic-cationic peptides to treat cholesterol-induced mitochondrial dysfunction
CN105939759B (zh) * 2013-12-02 2020-01-17 康德生物医疗技术公司 用于治疗白癜风的组合物和方法
WO2017066659A1 (en) * 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Jag1 expression predicts therapeutic response in nash
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
TW201822812A (zh) * 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療肥胖症的方法
CN108210914A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪代谢紊乱及其相关病症的药物及其用途
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
ES2085865T3 (es) * 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5468798A (en) * 1994-02-18 1995-11-21 Whitford Corporation Basecoat for a coating system
DE69630918T2 (de) * 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
JP2003511362A (ja) * 1999-10-04 2003-03-25 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー 新規カルバメートおよび尿素類
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
EP1303186B1 (en) * 2000-07-18 2011-01-26 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
EP2491943B1 (en) * 2003-02-04 2018-10-10 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
EP3167935B1 (en) * 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
WO2005051408A1 (en) * 2003-11-28 2005-06-09 Develogen Aktiengesellschaft Method for preventing and treating diabetes using dg119
RU2376028C2 (ru) * 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
EP1734963A4 (en) * 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2622911C (en) * 2005-09-16 2016-12-06 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
ES2458870T3 (es) * 2008-02-07 2014-05-07 Cornell University Procedimientos para prevenir o tratar la resistencia a la insulina
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
EP2944317A1 (en) * 2009-10-05 2015-11-18 Cornell University Methods for the prevention or treatment of heart failure

Also Published As

Publication number Publication date
CN107412724A (zh) 2017-12-01
ES2576746T3 (es) 2016-07-11
JP2018052983A (ja) 2018-04-05
WO2011019809A1 (en) 2011-02-17
HUE029550T2 (en) 2017-03-28
JP5909182B2 (ja) 2016-04-26
EP2464371A1 (en) 2012-06-20
EP2464371B1 (en) 2016-03-16
CA2770688A1 (en) 2011-02-17
CN105031605A (zh) 2015-11-11
US20110039766A1 (en) 2011-02-17
CN102647994A (zh) 2012-08-22
EP2464371A4 (en) 2013-02-20
EP3067061A1 (en) 2016-09-14
US20180104304A1 (en) 2018-04-19
EP3251686A1 (en) 2017-12-06
JP2017132782A (ja) 2017-08-03
JP2019104768A (ja) 2019-06-27
DK2464371T3 (en) 2016-06-27
JP2016041762A (ja) 2016-03-31
US20160199435A1 (en) 2016-07-14
EP3427746A1 (en) 2019-01-16
JP6271785B2 (ja) 2018-01-31
CA2770688C (en) 2018-06-05
JP2013501802A (ja) 2013-01-17
US20190209641A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
HK1247820A1 (zh) 預防或治療代謝綜合症的方法
HK1255283A1 (zh) 用於治療流感的化合物和方法
IL212348A0 (en) Treatment method
ZA201105679B (en) Methods for treating vascular leak syndrome
IL213619A0 (en) Treatment
GB0802116D0 (en) Treatment
EP2496227A4 (en) METHODS FOR TREATING A FIBROMYALGIA SYNDROME
HK1190936A1 (zh) 治療代謝綜合徵的方法和配方
GB0822011D0 (en) Treatment
EP2572730A4 (en) PROCESS FOR PROPHYLAXIS OR TREATMENT OF METABOLIC SYNDROME
IL217492A0 (en) Treatment method
IL220594A0 (en) Treatment method
EP2688402A4 (en) METHODS FOR THE TREATMENT OR PREVENTION OF UROLOGIC INFLAMMATION
GB0811992D0 (en) Treatment
GB0900599D0 (en) Treatment
IL229438A0 (en) Methods for treating obesity and/or metabolic syndrome
PL2263454T3 (pl) Kompozycja uzdatniająca
GB201001521D0 (en) Treatment
GB0913968D0 (en) Treatment
GB0820972D0 (en) Treatment
EP2609929A4 (en) COMPOSITION FOR PREVENTING OR TREATING DEMENTIA
GB0805912D0 (en) Treatment
GB0914371D0 (en) Treating wood
GB0820534D0 (en) Treatment
GB0820379D0 (en) Treatment